We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.14 | -6.86% | 1.90 | 1.84 | 1.96 | 2.01 | 2.00 | 2.00 | 1,925,128 | 16:35:20 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.81M | -0.0114 | -1.76 | 6.7M |
Date | Subject | Author | Discuss |
---|---|---|---|
09/1/2018 18:16 | Ny boy would you mind if i asked what you call your day job? | perfect pete | |
09/1/2018 18:07 | Could be just normal profit taking as some people right size their portfolios. | exploratory | |
09/1/2018 18:00 | Just a shame the mm's make their money in a way that inconveniences the PI.Although if you're a patient investor then the fun and games won't make a difference! | hamila01 | |
09/1/2018 17:57 | Probably dropping the price thereby triggering sell limits in order to collect shares. These shares are then used to satisfy a large order. | hamila01 | |
09/1/2018 17:55 | Call me cynical, but the 131k and 83,686 trades would be virtually impossible to fill on the back of 'standard' volume recently.... | sportbilly1976 | |
09/1/2018 17:27 | Anybody like to explain what the mm sre upto. By lowering price without news and low volume. Is that going to encourage holders to sell with results around the corner. Most would want to hold on? | ytsa2 | |
09/1/2018 17:12 | If good phase 3 results. I for one will be keeping the shares. The options after that kinda news will make it interesting to own the shares. | hamhamham1 | |
09/1/2018 17:08 | Thanks for the response guys. Lets say it has a successful phase 3 trial... Are the majority of you going to be in this for the long run and wait for a take over? Thanks. | btfd497 | |
09/1/2018 16:59 | By fall into place do you mean?: 1. Successful phase 3 - £5 minimum 2. FDA approval - £10 plus 2. Followed by licensing deal or takeover - £20 plus. OD | obiterdicta | |
09/1/2018 16:54 | If 'everything falls into place', £5.00 is nailed on and not the upper limit. IF. | waterloo01 | |
09/1/2018 16:52 | btfd497. Brave question here :) If all good, some say £5-15, others will say £40-100. Choose what you want :) | hamhamham1 | |
09/1/2018 16:49 | Roughly What price could this share rise to if everything falls into place? Only a rough ball mark would deb great. Many thanks. | btfd497 | |
09/1/2018 16:49 | Higher low. They'll have this up to 200p by the end of the week. | volsung | |
09/1/2018 16:48 | SCSW's nap is incidental anyway. Am here because I like the science and the results to date. | hamhamham1 | |
09/1/2018 16:42 | No not true AU I think. Just because their rec was concise and to the point doesn't at all mean they haven't done their homework and they usually meet the companies they tip to discuss at length. | spawny100 | |
09/1/2018 16:42 | Depends if you think there's a difference between their regular tips and their nap? | hamhamham1 | |
09/1/2018 16:36 | So no real 'homework' by SCSW; just a punt. No merit in that. 'It's anybody's guess' seems to be what is implied by naps like that. | aimingupward2 | |
09/1/2018 16:23 | Agree che7win, those shadowy MM’s some of us know how to play the game. | ny boy | |
09/1/2018 16:21 | Yeah, seems MMs were balanced with it falling Friday, the jump Monday on the tip caught them short, so a sharp drop today to fill the deficit, then back up from here. SCSW tip for 2018, they will have done their homework imho, would like to read it. | che7win | |
09/1/2018 16:17 | Mms played a blinder now to get this to 200p ? | lucicavi | |
09/1/2018 16:15 | Good review of pipeline developments in lupus. | stanman |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions